NSCLC
Conditions
Brief summary
Studies evaluating the effects of itraconazole or rifampicin on the pharmacokinetics of TY-9591 tablets in healthy subjects
Detailed description
To evaluate the pharmacokinetics of TY-9591 tablets in healthy Chinese subjects after a single oral administration. To evaluate the effects of itraconazole/rifampicin on the pharmacokinetics of TY-9591 and its metabolites D1 and D2 after oral administration of TY-9591 tablets.
Interventions
DRUGItraconazole
The study was divided into two sequences with a planned enrollment of 48 healthy adult subjects (24 in each sequence). PartA was the itraconazole study sequence, which was used to study the effect of itraconazole on the pharmacokinetic characteristics of TY-9591 tablets after multiple doses.
DRUGRifampicin
The study was divided into two sequences with a planned enrollment of 48 healthy adult subjects (24 in each sequence). PartB was the rifampin study sequence, which investigated the effect of multiple doses of rifampin on the pharmacokinetic profile of TY-9591 tablets.
Sponsors
TYK Medicines, Inc
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
PartA is the itraconazole study sequence,PartB was the rifampin study sequence.
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female healthy adult subjects aged 18-45 years old (inclusive), in which male or female accounted for no less than 1/4 of the total number of subjects in each sequence. 2. Body mass index (BMI) between 19.0 and 26.0 kg/m2 \[BMI= weight (kg)/ height 2 (m2)\] (including boundary values). 3. Participants (including male participants) were infertile themselves, or agreed to use highly effective nonpharmacologic contraceptive methods or abstain completely from sex for 6 months after the last dose of self-medication. 4. Subjects voluntarily participated and signed an informed consent form. 5. Subjects had good communication with investigators and were able to complete the trial in accordance with the protocol.
Exclusion criteria
1. Those with clinically significant abnormalities in physical examination, vital signs, routine laboratory tests (blood routine, urine routine, blood biochemistry, coagulation function), 12-lead electrocardiogram, ophthalmic examination, abdominal color Doppler ultrasound (liver, bile duct, pancreas, spleen, kidney), etc. 2. Persons with one or more positive results of human immunodeficiency virus (HIV) antibody, hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV) antibody, or treponema pallidum antibody (Anti-TP). 3. smokers with an average of more than 10 cigarettes per day in the previous 3 months or habitual users of nicotine products who could not quit during the study. 4. Heavy drinking or regular drinking in the 3 months before the screening period, i.e. drinking more than 14 units of alcohol per week (1 unit =360 mL of beer or 45 mL of 40% spirits or 150 mL of wine); Or alcohol breath test results on admission > 0.0 mg/100 mL and those who could not abstain from alcohol during the experiment. 5. those who consumed excessive amounts of tea, coffee, and/or caffeinated beverages (average \> 8 cups/day, 250 mL/cup) in the 3 months before the screening period, and those who could not stop using them during the study period. 6. those who took dragon fruit, mango, grapefruit, chocolate, any food or beverage containing caffeine, diet rich in xanthine, and other special diets affecting drug absorption, distribution, metabolism, and excretion within 7 days before taking the drug. 7. Use of any drugs that inhibit or induce the liver CYP3A4 enzyme (see Appendix II), herbs, or foods containing herbal ingredients within 30 days before the screening period. 8. taking any medicine (including Chinese herbal medicine and health supplements) within 14 days before taking the test drug. 9. enrollment in any drug clinical trial within 3 months before the screening period. 10. Subjects who may not be able to complete the study for other reasons or who are considered unsuitable for the study by the investigators.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Peak plasma concentrations (Cmax) of TY-9591 and its metabolites D1 and D2 | through study completion,an average of 6 months | Peak plasma concentrations (Cmax) of TY-9591 and its metabolites D1 and D2 |
| Area under the concentration-time curve from 0 to the last quantifiable time point after dose administration (AUC0-t) | through study completion,an average of 6 months | Area under the concentration-time curve from 0 to the last quantifiable time point after dose administration (AUC0-t) |
| Area under the concentration-time curve from 0 to infinity (AUC0-inf), as data permit | through study completion,an average of 6 months | Area under the concentration-time curve from 0 to infinity (AUC0-inf), as data permit |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| apparent clearance rate (CL/F) of TY-9591 and its metabolites D1 and D2 | through study completion,an average of 6 months | apparent clearance rate (CL/F) of TY-9591 and its metabolites D1 and D2 |
| apparent volume of distribution (Vd/F) of TY-9591 and its metabolites D1 and D2 | through study completion,an average of 6 months | apparent volume of distribution (Vd/F) of TY-9591 and its metabolites D1 and D2 |
| Time to peak concentration (Tmax) of TY-9591 and its metabolites D1 and D2 | through study completion,an average of 6 months | Time to peak concentration (Tmax) of TY-9591 and its metabolites D1 and D2 |
| Cmax ratio of metabolites to original drug | through study completion,an average of 6 months | Cmax ratio of metabolites to original drug |
| AUC ratio of metabolites to original drug | through study completion,an average of 6 months | AUC ratio of metabolites to original drug |
| mean retention time (MRT) of TY-9591 and its metabolites D1 and D2 | through study completion,an average of 6 months | mean retention time (MRT) of TY-9591 and its metabolites D1 and D2 |
| The half-life of elimination phase (t1/2) of TY-9591 and its metabolites D1 and D2 | through study completion,an average of 6 months | The half-life of elimination phase (t1/2) of TY-9591 and its metabolites D1 and D2 |
| elimination rate constant (λz) of TY-9591 and its metabolites D1 and D2 | through study completion,an average of 6 months | elimination rate constant (λz) of TY-9591 and its metabolites D1 and D2 |
Countries
China
Outcome results
None listed